<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Heart Test Laboratories Inc. Common Stock — News on 6ix</title>
<link>https://6ix.com/company/heart-test-laboratories-inc-common-stock</link>
<description>Latest news and press releases for Heart Test Laboratories Inc. Common Stock on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 14 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/heart-test-laboratories-inc-common-stock" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68357f9378dffbe2df0fb166.webp</url>
<title>Heart Test Laboratories Inc. Common Stock</title>
<link>https://6ix.com/company/heart-test-laboratories-inc-common-stock</link>
</image>
<item>
<title>HeartSciences Reminds Its Shareholders to Submit Their Vote at the Upcoming April 30, 2026, Annual Shareholders Meeting</title>
<link>https://6ix.com/company/heart-test-laboratories-inc-common-stock/news/heartsciences-reminds-its-shareholders-to-submit-their-vote-at-the-upcoming-april-30-2026-annual-shareholders-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/heart-test-laboratories-inc-common-stock/news/heartsciences-reminds-its-shareholders-to-submit-their-vote-at-the-upcoming-april-30-2026-annual-shareholders-meeting</guid>
<pubDate>Tue, 14 Apr 2026 04:00:00 GMT</pubDate>
<description>Southlake, TX, April 14, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”) a healthcare information</description>
</item>
<item>
<title>HeartSciences’ MyoVista Insights™ Receives Epic Toolbox Designation for ECG Management System Category</title>
<link>https://6ix.com/company/heart-test-laboratories-inc-common-stock/news/heartsciences-myovista-insightstm-receives-epic-toolbox-designation-for-ecg-management-system-category</link>
<guid isPermaLink="true">https://6ix.com/company/heart-test-laboratories-inc-common-stock/news/heartsciences-myovista-insightstm-receives-epic-toolbox-designation-for-ecg-management-system-category</guid>
<pubDate>Wed, 25 Mar 2026 04:00:00 GMT</pubDate>
<description>Southlake, TX , March 25, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information</description>
</item>
<item>
<title>HeartSciences to Present at Investor Summit Group Virtual Conference and Host Virtual One on One Investor Meetings</title>
<link>https://6ix.com/company/heart-test-laboratories-inc-common-stock/news/heartsciences-to-present-at-investor-summit-group-virtual-conference-and-host-virtual-one-on-one-investor-meetings</link>
<guid isPermaLink="true">https://6ix.com/company/heart-test-laboratories-inc-common-stock/news/heartsciences-to-present-at-investor-summit-group-virtual-conference-and-host-virtual-one-on-one-investor-meetings</guid>
<pubDate>Tue, 24 Mar 2026 15:18:00 GMT</pubDate>
<description>Southlake, TX, March 24, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), will present at Investor Summit Group Virtual Conference, March 25, 2026 at 12:30 pm ET. Hosted by Investor Summit Group, a premier platform connecting microcap companies with leading investors, the event</description>
</item>
<item>
<title>HeartSciences Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/heart-test-laboratories-inc-common-stock/news/heartsciences-reports-fiscal-third-quarter-2026-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/heart-test-laboratories-inc-common-stock/news/heartsciences-reports-fiscal-third-quarter-2026-financial-results-and-provides-business-update</guid>
<pubDate>Mon, 16 Mar 2026 20:15:00 GMT</pubDate>
<description>Southlake, Texas, March 16, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today reported financial results for its fiscal third quarter ended January 31, 2026 (“FQ3 2026”) and provided a business update. Third Quarter and Recent Highlights During the third quarter and subseq</description>
</item>
<item>
<title>University of West England Adopts HeartSciences’ MyoVista Insights™ Platform and MyoVista® wavECG™ Device to Establish ECG Education and Technology Reference Center</title>
<link>https://6ix.com/company/heart-test-laboratories-inc-common-stock/news/university-west-england-adopts-heartsciences-133000372</link>
<guid isPermaLink="true">https://6ix.com/company/heart-test-laboratories-inc-common-stock/news/university-west-england-adopts-heartsciences-133000372</guid>
<pubDate>Thu, 05 Feb 2026 13:30:00 GMT</pubDate>
<description>Southlake, TX, Feb. 05, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today announced that the University of the West of England (“UWE”) has adopted the Company’s MyoVista Insights™ platform and MyoVista® wavECG™ device as its exclusive ECG technologies to establish a Reference Center</description>
</item>
<item>
<title>Cibolo Health Designates HeartSciences’ MyoVista Insights™ as Endorsed ECG Management Platform for Network of 123 Independent Hospitals</title>
<link>https://6ix.com/company/heart-test-laboratories-inc-common-stock/news/cibolo-health-designates-heartsciences-myovista-133000712</link>
<guid isPermaLink="true">https://6ix.com/company/heart-test-laboratories-inc-common-stock/news/cibolo-health-designates-heartsciences-myovista-133000712</guid>
<pubDate>Thu, 29 Jan 2026 13:30:00 GMT</pubDate>
<description>Southlake, TX, Jan. 29, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today announced that Cibolo Rural Health Networks (“Cibolo Health”) has selected MyoVista Insights™ as its endorsed ECG management platform for independent hospitals within its high-value networks. This co</description>
</item>
<item>
<title>HeartSciences Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/heart-test-laboratories-inc-common-stock/news/heartsciences-reports-fiscal-second-quarter-211500775</link>
<guid isPermaLink="true">https://6ix.com/company/heart-test-laboratories-inc-common-stock/news/heartsciences-reports-fiscal-second-quarter-211500775</guid>
<pubDate>Mon, 15 Dec 2025 21:15:00 GMT</pubDate>
<description>Southlake, TX, Dec. 15, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today reported financial results for its fiscal second quarter ended October 31, 2025 (“FQ2 2026”) and provided a business update. Second Quarter and Recent Highlights During the second quarter and subsequent per</description>
</item>
<item>
<title>HeartSciences Announces FDA 510(k) Submission for MyoVista® wavECG™ Device</title>
<link>https://6ix.com/company/heart-test-laboratories-inc-common-stock/news/heartsciences-announces-fda-510-k-133000599</link>
<guid isPermaLink="true">https://6ix.com/company/heart-test-laboratories-inc-common-stock/news/heartsciences-announces-fda-510-k-133000599</guid>
<pubDate>Mon, 15 Dec 2025 13:30:00 GMT</pubDate>
<description>Southlake, TX, Dec. 15, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company advancing the use of ECG/EKGs through the integration of artificial intelligence (“AI”), today announced it has submitted its MyoVista® wavECG™ device to the U.S. Food and Drug Administration (“FDA”) for 510(k) premarket clearance. The MyoVista wavECG device is designed to provide conventional ECG functionality while ser</description>
</item>
<item>
<title>HeartSciences Announces Major Upgrade to User Features of MyoVista Insights Platform with Commercial Launch Version 1.1</title>
<link>https://6ix.com/company/heart-test-laboratories-inc-common-stock/news/heartsciences-announces-major-upgrade-user-133000900</link>
<guid isPermaLink="true">https://6ix.com/company/heart-test-laboratories-inc-common-stock/news/heartsciences-announces-major-upgrade-user-133000900</guid>
<pubDate>Thu, 11 Dec 2025 13:30:00 GMT</pubDate>
<description>Version 1.1 Designed to Provide Best Usability of any ECG SystemSouthlake, TX, Dec. 11, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company advancing the use of ECG/EKGs through the integration of artificial intelligence (“AI”), today announced the commercial release of MyoVista Insights™ version 1.1, a major update that is built to provide the most usable ECG system and enhances clinical interp</description>
</item>
<item>
<title>HeartSciences Provides Business Update and Reports First Quarter of Fiscal 2026 Financial Results</title>
<link>https://6ix.com/company/heart-test-laboratories-inc-common-stock/news/heartsciences-provides-business-reports-first-201500437</link>
<guid isPermaLink="true">https://6ix.com/company/heart-test-laboratories-inc-common-stock/news/heartsciences-provides-business-reports-first-201500437</guid>
<pubDate>Thu, 11 Sep 2025 20:15:00 GMT</pubDate>
<description>Southlake, TX, Sept. 11, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (“AI”)-powered medical technology company transforming ECGs/EKGs to enable earlier detection of heart disease, today announced its financial results for the first quarter of fiscal 2026 ended July 31, 2025 (“FQ1 2026”) and provided a business update highlighting continued progress. First Quarter and Recent Highlights HeartSciences has made subs</description>
</item>
<item>
<title>HeartSciences Announces Conference Participation and Investor Webinar</title>
<link>https://6ix.com/company/heart-test-laboratories-inc-common-stock/news/heartsciences-announces-conference-participation-investor-130000871</link>
<guid isPermaLink="true">https://6ix.com/company/heart-test-laboratories-inc-common-stock/news/heartsciences-announces-conference-participation-investor-130000871</guid>
<pubDate>Fri, 15 Aug 2025 13:00:00 GMT</pubDate>
<description>Virtual Events Include Investor Webinar and Presentation at Emerging Growth Conference 85Southlake, TX, Aug. 15, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (“AI”)-powered medical technology company transforming ECGs/EKGs to enable earlier detection of heart disease, today announced its participation in multiple virtual events during the month of August. These events are intended to further introduce HeartScienc</description>
</item>
<item>
<title>HeartSciences Provides Business Update and Reports Fiscal 2025 Financial Results</title>
<link>https://6ix.com/company/heart-test-laboratories-inc-common-stock/news/heartsciences-provides-business-reports-fiscal-201500745</link>
<guid isPermaLink="true">https://6ix.com/company/heart-test-laboratories-inc-common-stock/news/heartsciences-provides-business-reports-fiscal-201500745</guid>
<pubDate>Thu, 24 Jul 2025 20:15:00 GMT</pubDate>
<description>Southlake, TX, July 24, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (“AI”)-powered medical technology company transforming ECGs/EKGs to enable earlier detection of heart disease, today announced its financial results for the fiscal year ended April 30, 2025, and provided a business update highlighting significant strategic progress. Fiscal 2025 and Business Highlights HeartSciences made substantial advancements</description>
</item>
<item>
<title>HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis</title>
<link>https://6ix.com/company/heart-test-laboratories-inc-common-stock/news/heartsciences-receives-fda-breakthrough-device-130000655</link>
<guid isPermaLink="true">https://6ix.com/company/heart-test-laboratories-inc-common-stock/news/heartsciences-receives-fda-breakthrough-device-130000655</guid>
<pubDate>Wed, 04 Jun 2025 13:00:00 GMT</pubDate>
<description>Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration with Hospital EHR SystemsSouthlake, TX, June 04, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (“AI”) powered medical technology company focused on advancing the capabilities of ECGs/EKGs for the earlier detection of heart disease, today announced that the U.S. Food an</description>
</item>
<item>
<title>Foundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences’ Patent Portfolio and IP Value</title>
<link>https://6ix.com/company/heart-test-laboratories-inc-common-stock/news/foundational-us-patent-granted-ecg-130000829</link>
<guid isPermaLink="true">https://6ix.com/company/heart-test-laboratories-inc-common-stock/news/foundational-us-patent-granted-ecg-130000829</guid>
<pubDate>Tue, 03 Jun 2025 13:00:00 GMT</pubDate>
<description>Patent covers estimation of measures of heart function using an ECG, which are critical in the diagnosis and early detection of heart diseaseSouthlake, TX, June 03, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (“AI”) powered medical technology company focused on transforming ECGs/EKGs to enable earlier detection of heart disease, today announced the grant by the United States Patent and Trademark Office (USPTO) o</description>
</item>
<item>
<title>HeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial Milestone</title>
<link>https://6ix.com/company/heart-test-laboratories-inc-common-stock/news/heartsciences-signs-first-myovista-insights-130000491</link>
<guid isPermaLink="true">https://6ix.com/company/heart-test-laboratories-inc-common-stock/news/heartsciences-signs-first-myovista-insights-130000491</guid>
<pubDate>Thu, 29 May 2025 13:00:00 GMT</pubDate>
<description>Southlake, TX, May 29, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (“AI”)-powered medical technology company focused on transforming ECGs/EKGs to enable earlier detection of heart disease, today announced the signing of its first commercial customer for the MyoVista Insights™ platform: Westcliffe Health Innovations, based in the United Kingdom. This milestone follows the recent launch of MyoVista Insights and th</description>
</item>
<item>
<title>HeartSciences’ CEO Andrew Simpson to Present at Emerging Growth Conference 82 on Wednesday, May 21, 2025</title>
<link>https://6ix.com/company/heart-test-laboratories-inc-common-stock/news/heartsciences-ceo-andrew-simpson-present-130000271</link>
<guid isPermaLink="true">https://6ix.com/company/heart-test-laboratories-inc-common-stock/news/heartsciences-ceo-andrew-simpson-present-130000271</guid>
<pubDate>Tue, 20 May 2025 13:00:00 GMT</pubDate>
<description>Southlake, TX, May 20, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq:HSCS) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that Chief Executive Officer Andrew Simpson will deliver a live presentation and participate in a Q&A session at the Emerging Growth Conference 82. Event Details: Date: Wednesday, May 21, 2025 Time: 10:15 AM</description>
</item>
<item>
<title>HeartSciences to Host Investor Webinar and Q&A on Wednesday May 14, 2025 - Featuring CEO Andrew Simpson</title>
<link>https://6ix.com/company/heart-test-laboratories-inc-common-stock/news/heartsciences-host-investor-webinar-q-130000230</link>
<guid isPermaLink="true">https://6ix.com/company/heart-test-laboratories-inc-common-stock/news/heartsciences-host-investor-webinar-q-130000230</guid>
<pubDate>Thu, 08 May 2025 13:00:00 GMT</pubDate>
<description>Southlake, TX, May 08, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq:HSCS) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that it will host a live investor webinar on Wednesday, May 14, 2025, at 2:00 p.m. EDT | 11:00 a.m. PDT, featuring a presentation and Q&A session with CEO Andrew Simpson. Register Now To attend the webinar an</description>
</item>
<item>
<title>HeartSciences Adds Prominent Key Advisors to its Scientific Advisory Board</title>
<link>https://6ix.com/company/heart-test-laboratories-inc-common-stock/news/heartsciences-adds-prominent-key-advisors-130000887</link>
<guid isPermaLink="true">https://6ix.com/company/heart-test-laboratories-inc-common-stock/news/heartsciences-adds-prominent-key-advisors-130000887</guid>
<pubDate>Wed, 07 May 2025 13:00:00 GMT</pubDate>
<description>Southlake, TX, May 07, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq:HSCS) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Dr. Girish Nadkarni, MD, Dr. Joshua Lampert, MD, and Dr. Akhil Vaid, MBBS, to its Scientific Advisory Board. These appointments underscore HeartSciences' commitment to advancing and transfo</description>
</item>
<item>
<title>HeartSciences Announces Launch of MyoVista Insights™ Platform and Related Early Adopter Program</title>
<link>https://6ix.com/company/heart-test-laboratories-inc-common-stock/news/heartsciences-announces-launch-myovista-insights-130000099</link>
<guid isPermaLink="true">https://6ix.com/company/heart-test-laboratories-inc-common-stock/news/heartsciences-announces-launch-myovista-insights-130000099</guid>
<pubDate>Thu, 01 May 2025 13:00:00 GMT</pubDate>
<description>Southlake, TX, May 01, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence ("AI")-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced today that it has launched the MyoVista InsightsTM platform and related early adopter program for select reference sites. MyoVista Insights is a cloud-native next-generation ECG Management System designed</description>
</item>
<item>
<title>HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2025 Financial Results</title>
<link>https://6ix.com/company/heart-test-laboratories-inc-common-stock/news/heartsciences-provides-business-reports-third-201500863</link>
<guid isPermaLink="true">https://6ix.com/company/heart-test-laboratories-inc-common-stock/news/heartsciences-provides-business-reports-third-201500863</guid>
<pubDate>Thu, 13 Mar 2025 20:15:00 GMT</pubDate>
<description>Southlake, TX, March 13, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (“AI”)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the third quarter fiscal 2025 ended January 31, 2025 and provided a business update. Third Fiscal Quarter 2025 Highlights: During the third quarter of fiscal year 2025 (“Q3 FY</description>
</item>
</channel>
</rss>